Your browser doesn't support javascript.
loading
Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
Henry, David H; Gordan, Lucio N; Charu, Veena; Wilhelm, Francois E; Williams, Denise; Xie, John; Woodman, Richard C.
Affiliation
  • Henry DH; Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, PA, USA.
Curr Med Res Opin ; 22(7): 1403-13, 2006 Jul.
Article in En | MEDLINE | ID: mdl-16834839
OBJECTIVE: This randomized, open-label, multicenter study compared the efficacy and safety of epoetin alfa (EPO) 80 000 U every 2 weeks (Q2W) to the FDA-approved regimen of 40 000 U weekly (QW) in patients with chemotherapy-induced anemia. RESEARCH DESIGN AND METHODS: A total of 310 patients with nonmyeloid malignancy and baseline hemoglobin (Hb)
Subject(s)
Search on Google
Database: MEDLINE Main subject: Erythropoietin / Hematinics / Anemia Type of study: Clinical_trials / Guideline / Observational_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Curr Med Res Opin Year: 2006 Type: Article Affiliation country: United States
Search on Google
Database: MEDLINE Main subject: Erythropoietin / Hematinics / Anemia Type of study: Clinical_trials / Guideline / Observational_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Curr Med Res Opin Year: 2006 Type: Article Affiliation country: United States